Trial Profile

A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 0120 (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors Gracell Biotechnology

Most Recent Events

23 Jan 2024 Status changed to recruiting.
13 Nov 2023 According to a Gracell Biotechnology media release, trial is expected to initiate in the fourth quarter of 2023.
26 Sep 2023 According to a Gracell Biotechnology media release, the company plans to commence this trial imminently.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com